(MENAFN- GlobeNewsWire - Nasdaq) Increasing investments in aptamer Research & Development (R&D) and rapid technological advancements in aptamers are key factors driving aptamers market revenue growth.Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global aptamers market size was USD 1.80 Billion in 2022 and is expected to register a rapid revenue CAGR of 24.22% during the forecast period. Increasing investments in aptamer Research & Development (R&D) and rapid technological advancements in aptamers are key factors driving market revenue growth.
Increasing prevalence of chronic disease is another key factor driving revenue growth of the market. World Health Organization (WHO) estimated that 71% individuals died globally due to chronic disease. Over 7 out of 10 deaths are caused by chronic diseases, such as heart disease, stroke, cancer, diabetes, and chronic respiratory diseases. While the prevalence of chronic disease varies by age and diagnosis, people of all ages everywhere around the world are affected. Unhealthy lifestyles, environmental factors, and aging population are the main reasons of chronic disease. Aptamers have the potential to revolutionize the treatment of chronic diseases by offering a range of advantages over traditional therapies. There are some treatment strategies for this disease such as targeted drug delivery, gene therapy, and immunomodulation.
Furthermore, leading companies developing aptamers is another factor driving market revenue growth. For instance, on 20 July 2023, Zentek and McMaster University announced positive results for their aptamer-based technology with therapeutic potential. The technology has been shown to be effective in pre-clinical animal models of SARS-CoV-2 infection. This announcement shows Zentek's aptamer-based technology has the potential to eliminate the need for traditional therapies for SARS-CoV-2 infection such as monoclonal antibodies.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @
However, high cost in aptamers development is a key factor, which could restrain market revenue growth. The Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process, which is used to select aptamers, is a time-consuming and labor-intensive process. This makes it expensive to develop aptamers for new targets. In addition, cost of aptamer synthesis, aptamer modification, and aptamer clinical trials and limited understanding of aptamers among healthcare professionals, researchers, and potential users are other factors, which could also restrain market revenue growth.
Segment Insights
Type Insights:
On the basis of type, the global aptamers market is segmented into nucleic acid aptamer and peptide aptamers. The nucleic acid aptamer segment accounted for largest revenue share in the global aptamers market in 2022 attributed to rising number of pharmaceutical companies investing heavily in the development of nucleic acid aptamers to treat chronic diseases. This is due to numerous advantages of nucleic acid over traditional antibodies such as their small size, stability, and ability to be modified to improve their properties. Nucleic acid aptamers are typically composed of either Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA) and are selected from a large pool of random sequences using a process called SELEX.
For instance, on 6 May, 2021, NEC Solution announced the development of artificial DNA aptamers. This has been developed for SARS-CoV-2 is able to bind to the virus's spike protein, which is used to develop rapid and accurate diagnostic tests for SARS-CoV-2. This adds NEC Solution Innovator's lineup by eliminating the need for traditional antibody-based diagnostic tests for SARS-CoV-2.
Application Insights:
On the basis of application, the aptamers market is segmented into diagnostic, therapeutic, R&D, and others. The R&D segment is expected to account for significantly large revenue share in the global aptamers market during the forecast period due to rising prevalence of chronic disease such as cancer, diabetes, and infectious diseases. R&D is leading to the development of aptamers for a wider range of treatment in cancer. Aptamers are largely used in cancer therapeutics to target various receptors present on cancer cells. American Cancer Society estimated there are 1.9 million new cancer cases and 609,360 cancer deaths in 2022. World Health Organization (WHO) estimated there were 2.26 million breast cancer, 2.21 million lung cancer, and 1.41million Prostate cancer.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @
Regional Insights:
The North America market accounted for largest revenue share in the global aptamers market in 2022 due to rising prevalence of chronic diseases. In 2022, Center for Disease Control and Prevention (CDC) estimated there were six in ten adults living with a chronic disease such as cancer, heart disease, or diabetes in the U.S. Chronic diseases are among the leading causes of death in the U.S. along with heart disease and cancer alone accounting for around 38% of all deaths. About 695,000 people in the U.S. died from heart disease in 2021.
The Asia Pacific market is expected to register fastest revenue growth rate in the global aptamers market over the forecast period due to rising prevalence of cancer. According to WHO, in the South-East Asia Region, an estimated 2.3 million people developed cancer in 2020, and 1.4 million died of the disease. In addition, increasing awareness about aptamers' potential, and rising demand for aptamer technology are other factors driving market revenue growth of this region. For instance, on 24 January 2023, Aptamer Group plc announced a new contract with an Asian-based developer of custom enzymes for the development of optimer binders for incorporation into a biosensor. This novel biosensor technology incorporates optimer binders to provide precise and efficient monitoring of critical ingredients during manufacturing. This announcement enhances Aptamer Group's product offerings by providing a novel solution for incorporating optimer binders into biosensors.
Scope of Research
| Report Details | Outcome |
| Market Size in 2022 | USD 1.80 Billion |
| CAGR (2023–2032) | 24.22% |
| Revenue Forecast To 2032 | USD 13.5 Billion |
| Base Year For Estimation | 2022 |
| Historical Data | 2019–2021 |
| Forecast Period | 2023–2032 |
| Quantitative Units | Revenue in USD Billion and CAGR in % from 2023 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Type, technology, application, end-use, and region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Russia, Rest of Europe, China, India, Japan, South Korea, ASEAN Countries, Oceania, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
| Key Companies Profiled | Aptamer Group, Aptadel Therapeutics, SomaLogic Operating co; Inc., Base Pair Biotechnologie, Vivonics, Inc, Aptagen, LLC, Aptus Biotech, TriLink BioTechnologies , AM BIOTECHNOLOGIES, LLC, and Maravai LifeSciences |
| Customization Scope | 10 hours of free customization and expert consultation |
Direct Order Can Be Placed Through This Link [Exclusive Copy] @
Major Companies and Competitive Landscape
The global aptamers market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing a more effective aptamers products in the market. Some major players included in the global aptamers market report are:
Aptamer Group Aptadel Therapeutics SomaLogic Operating Co., Inc. Base Pair Biotechnologies Vivonics, Inc Aptagen, LLC Aptus Biotech TriLink BioTechnologies AM BIOTECHNOLOGIES, LLC Maravai LifeSciences
Strategic Development
On 23 May 2022, Aptamer Group announced its partnership with PinotBio for the development of Optimer drug conjugates to target different cancer diseases. This announcement reinforces Cybrexa Therapeutics' commitment to supplying patients by ending the need for chemotherapy in the treatment of breast cancer. On 5 March 2021, Aptamer announced its collaboration with AstraZeneca to explore the potential of optimer-based strategies for targeted renal drug delivery. Optimer binders offer a promising solution to this challenge by enabling targeted delivery of drugs to specific renal cells. This collaboration aims to leverage the unique properties of optimer binders to develop novel drug delivery vehicles, known as optimer-drug conjugates.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @
Segments Covered in Report
For the purpose of this report, Emergen Research has segmented the global aptamers market on the basis of type, technology, Application, end-use, and region:
Type outlook (Revenue, USD Billion; 2019-2032) Nucleic Acid Aptamers Peptide Aptamers
Technology Outlook (Revenue, USD Billion; 2019-2032) Systematic Evolution of Ligands By Exponential Enrichment (SELEX) Others
Application Outlook (Revenue, USD Billion; 2019-2032) Diagnostic Therapeutic Research & Development (R&D) Others
End-use Outlook (Revenue, USD Billion; 2019-2032) Pharmaceutical & Biotechnology Industry Research Institute Contract Research Organizations (CROs) Others
Regional Outlook (Revenue, USD Billion; 2019–2032) North America U.S. Canada Europe Germany France UK Italy Spain Benelux Russia Rest of Europe Asia Pacific China Japan South Korea India ASEAN Countries Oceania Rest of APAC Latin America Brazil Mexico Rest of LATAM Middle East & Africa GCC Countries Israel Turkey South Africa Rest of Middle East & Africa
Emergen Research is Offering Exclusive Customization as per your Specific Requirements @
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web:
Direct Line: +1 (604) 757-9756
E-mail: ...
Explore Our Blogs and Insights Section: insights
MENAFN15012024004107003653ID1107722050
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.